SLS - SELLAS Life Sciences Group, Inc. 0 WATCHERS

$SLS next

$SLS for Monday SLS is showing strong momentum and growing trader interest, making it a compelling watch for anyone looking for a potential breakout setup. With its recent volume surge and increased attention on catalysts in its pipeline, buyers are positioning early in case momentum continues. If that strength carries …

$SLS on the watch for Monday SLS is showing strong momentum and growing trader interest, making it a compelling watch for anyone looking for a potential breakout setup. With its recent volume surge and increased attention on catalysts in its pipeline, buyers are positioning early in case momentum continues. If …

Keep your eye on $SLS Monday SLS is showing strong momentum and growing trader interest, making it a compelling watch for anyone looking for a potential breakout setup. With its recent volume surge and increased attention on catalysts in its pipeline, buyers are positioning early in case momentum continues. If …

$SLS is the Monday pre-market play

SLS could announce their positive (or negative) Phase 3 AML results any day. Announcement from SPRO that the NDA for their antibiotic was filed also due any day now.

spend $30,000 (1% of your portfolio) of it on SLS stock and then wait for it to 100x after successful trial results and double your net worth and retire

Take a look at SLS. Expected to report results from acute myeloid leukemia Phase 3 trail before years end. Small biotechs with cancer news have been rocketing up lately, even if the news is only Phase 1, 2, or sometimes even just some garbage preclinical crap. Be aware of the …

Not really, snake oil. Should have went with $SLS.

SLS about to do the same - mark this post.

Why Bristol Myers Squibb Should Buy SLS (Sellas) sry* Strong commitment to oncology and immunotherapy; has made further major deals in 2025 and is likely interested in new cancer therapies. I contacted Bristol Myers Squibb today to point out that SELLAS has candidates in the cancer/hematology field with galinpepimut-S (GPS) …

My top 5 penny biotechs in order of preference, baby: 1. SPRO, 2. SLS, 3. MIST, 4. DRTS, 5. SCYX. First 3 have events coming up in next 1 or 2 months that could move the stock either up or down. Last 2 are longer-term plays.

Not sure how short term you mean, but my current "short term" 10x is SLS (sellas life sciences). Recently plummeted after a dilution event that gave them a full cash runway thru 2026. Price action seems to be deliberately consolidating in 1.40-1.50 range. Might dip to 1.25 but doubtful any …

Biotechs I like SLS, SPRO, SCYX, baby

SLS trials lasting longer is a good sign GPS works. Patience, grasshopper.

SLS

Viking Therapeutics (VKTX) had the best weight loss data in their phase2 trial, better dan Novo and Lilly. They will either go it alone and become part of the obesity gravy train, or more likely, will soon be bought by a big pharma company for at least 4x the current …

ONDS, ASTS, ALRT, SLS, RVPH, GOOG

SLS is currently in an accumulation zone after a big ugly drop off. The drop almost looks intentional, as if the price is being suppressed for accumulation purposes. They are waiting for their last patient to die in a phase 3 study, who has already outlived the expectations and was …

SLS if the Phase 3 trial in acute myeloid leukemia (AML) is successful. Market cap of \~220m, \~20% of the float is short. The trial results are supposed to be unblinded upon the 80th death (125 patients in the trial). The 60th death was in early Dec 2024 and it …

DVLT NFE Long term holds: SLS

SLS

WWR is in a very good position to build graphite mine and production facilities. I know people forgot about them after the critical minerals rally, but don't underestimate their position. PLSR plans ten new appraisal wells, which is a bit insane but mostly funded by warrants that have already been …

Bright green earlier today. Now a little red. Still not buying or selling *anything* until SLS or AZTR pop.

SLS - Phase 3 results worth 100x the market cap, expected any day and by the end of the year.

Just waiting for SLS, AZTR, and PLSR news to drop. Whole market's either a falling knife or a bull trap and I don't care to find out which.

SLS worth it??

Im in for SLS and Ganx

Check out SLS … potentially the same gains possible by EOY - Q1 2026. NFA DYOR.

SLS – $1.43 may be the last discounted entry before a pivotal Phase 3 readout worth >$50,- EOY SELLAS Life Sciences is approaching the completion of its Phase 3 REGAL trial in AML, an overall-survival study that ends at 80 events. Historically, CR2 AML patients survive roughly 6–8 months, so …

SLS – $1.41 may be the last discounted entry before a pivotal Phase 3 readout worth >$50,- EOY SELLAS Life Sciences is approaching the completion of its Phase 3 REGAL trial in AML, an overall-survival study that ends at 80 events. Historically, CR2 AML patients survive roughly 6–8 months, so …